Drug intelligence / Profile preview

EMB-07

Development stage: Phase 2
Lead developer: EpimAb Biotherapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

EMB-07 is a bispecific antibody designed to redirect T cells for cancer immunotherapy. It targets both the tumor-associated antigen receptor tyrosine kinase-like orphan receptor 1 (ROR1) and the T-cell surface antigen CD3. By binding to ROR1 on tumor cells and CD3 on T lymphocytes, EMB-07 recruits and activates T cells at the tumor site, promoting cytotoxic activity against cancer cells. The drug is developed using EpimAb’s proprietary FIT-Ig (Fabs-In-Tandem Immunoglobulin) technology. Preclinical studies have shown promising efficacy and safety profiles. EMB-07 is currently in Phase I clinical trials for various solid tumors and lymphomas[1][2][5][6].

Other names: anti-ROR1/anti-CD3 bispecific antibody

Targets

ROR1 (Receptor tyrosine kinase-like orphan receptor 1)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on EMB-07.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EMB-07.

Explore the full profile